SCHEMBL6093388

SCHEMBL6093388

O=C1c2c(-c3ccc(F)cc3)cc(N3CCC(N4CCOCC4)CC3)nc2OCCCN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 5/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
PIK3CD O00329 2/20 0.34
PIK3CA P42336 2/20 0.34
PIK3CB P42338 2/20 0.34
TNIK Q9UKE5 3/20 0.34
ATM Q13315 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
AURKA O14965 1/20 0.34
FLT1 P17948 1/20 0.34
GCK P35557 1/20 0.34
FLT4 P35916 1/20 0.34
MAP3K11 Q16584 1/20 0.34
STK17A Q9UEE5 1/20 0.34
ENPP2 Q13822 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092544 0.95 TACR1 (0.38) TACR1ROCK2ROCK1TNIKAURKA
SCHEMBL6094210 0.89 TACR1 (0.37) TACR1ROCK2ROCK1TNIKHRH3
SCHEMBL6093672 0.89 TACR1 (0.40) TACR1ROCK2ROCK1HRH3CASP1
SCHEMBL6093680 0.88 CYP2D6 (0.38) TACR1ROCK2ROCK1TNIKATM
SCHEMBL6096328 0.88 TACR1 (0.38) TACR1ROCK2ROCK1TNIKCYP3A4
SCHEMBL6092004 0.88 TACR1 (0.39) TACR1ROCK2ROCK1HRH3
SCHEMBL6093917 0.87 TACR1 (0.40) TACR1PIK3CDPIK3CAPIK3CBCYP3A4
SCHEMBL6092166 0.86 CNR1 (0.39) TACR1ROCK2ROCK1TNIKCYP2D6
SCHEMBL6094098 0.85 SMO (0.40) TACR1ROCK2ROCK1PIK3CATNIK
SCHEMBL15680031 0.84 TACR1 (0.36) TACR1ROCK2ROCK1TNIKHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030107-B2 nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction KYORIN PHARMACEUTICAL.CO., LTD. (JP) 2006-04-18 US disclosed
US-20050107375-A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-05-19 US disclosed
EP-1457493-A1 FUSED BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS Kyorin Pharmaceutical Co., Ltd. (JP) 2004-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107375-A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists BDKRB1, BDKRB2, TACR1 TACR1 3/4885ROCK2 3047/4885ROCK1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.